Please Wait
Applying Filters...
menu
    • menu
    Douglas CDMO-PSE
    News
    CDMOs' Role in Supporting US Generic Drug Development

    01 Jul 2025

    // PRESS RELEASE

    End-to-End CDMOs: Seamless Path to Market

    20 May 2025

    // PRESS RELEASE

    Mid-Sized CDMOs Offer Strategic Advantages

    12 May 2025

    // PRESS RELEASE

    Data Compilation
    #PharmaFlow

    Douglas CDMO

    Contact Supplier

    Website

    CPhI WW Frankfurt

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/_DSPm0HktWM
    Left Arrow
    Right Arrow

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Related CompaniesRelated Companies

    About

    Douglas CDMO, based in New Zealand, has a history dating back to 1967. We offer end-to-end integrated drug development services, specializing in formulating and commercially supplying innovative and generic high-potency small molecule softgels and liquids. Our capabilities extend to producing prescription drugs across key therapeutic areas, including dermatology, oncology, endocrinology and the central nervous system. Working with clients across the globe, we pride ourselves on delivering superior quality and excellent service, ensuring our partners achieve successful, timely outcomes. Contact our team of experts. We are happy to help.